Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial

Ophthalmology

Volumn 124, Issue 9, 2017, Pages 1296-1304

  Dugel, Pravin U ^a,b   Jaffe, Glenn J ^c   Sallstig, Peter ^d   Warburton, James ^e   Weichselberger, Andreas ^d   Wieland, Mark ^f,g   Singerman, Lawrence ^h,i  

^a RETINAL CONSULTANTS OF ARIZONA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c DUKE UNIVERSITY   (United States)

^d ALCON RESEARCH LTD   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^g STANFORD UNIVERSITY   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BROLUCIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; BEST CORRECTED VISUAL ACUITY; BLURRED VISION; CATARACT; CENTRAL SUBFIELD THICKNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; FOREIGN BODY; HEART MUSCLE ISCHEMIA; HUMAN; IRIDOCYCLITIS; LOADING DRUG DOSE; MACULAR FIBROSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS CARCINOMA; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERY ELDERLY; VISUAL SYSTEM PARAMETERS; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 85019574224     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2017.03.057     Document Type: Conference Paper

References (9)

1. Bloch, S.B., Larsen, M., Munch, I.C., Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153 (2012), 209–213.e2.
2. Jonas, J.B., Bourne, R.R., White, R.A., et al. Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis. Am J Ophthalmol 158 (2014), 808–815.
3. ® guidelines. Age-related macular degeneration. Available at: www.aao.org/ppp. Accessed April 8, 2015.
4. Schmidt-Erfurth, U., Chong, V., Loewenstein, A., et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98 (2014), 1144–1167.
5. Holz, F.G., Schmitz-Valckenberg, S., Fleckenstein, M., Recent developments in the treatment of age-related macular degeneration. J Clin Invest 124 (2014), 1430–1438.
6. Heier, J.S., Brown, D.M., Chong, V., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119 (2012), 2537–2548.
7. Gaudreault, J., Gunde, T., Floyd, H.S., et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. [abstract]. Invest Ophthalmol Vis Sci, 53, 2012, 3025.
8. Tietz, J., Schmid, G., Konrad, J., et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor ɑ for the treatment of retinal disorders. Invest Ophthalmol Vis Sci, 56, 2015, 1501.
9. Holz, F.G., Dugel, P.U., Weissgerber, G., et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology 123 (2016), 1080–1089.